Volume 9 Supplement 2
Alloantigenic recognition properties of CD8+ regulatory T cells
© Picarda et al; licensee BioMed Central Ltd. 2011
Published: 23 November 2011
We recently reported that in a rat major histocompatibility complex (MHC) mismatched heart allograft model, treatment with CD40Ig, a chimeric molecule that blocks CD40L, leads to indefinite allograft survival mediated by CD8+CD45RClow Tregs . Although essential, the exact role of TCR/MHC/peptide interaction in Treg activity is still unknown. We therefore characterize the allogeneic peptide(s) recognized and the TCR usage of the CD8+CD45RClow Tregs.
Material and methods
Allogeneic peptide(s) were derived from polymorphic regions of donor MHC molecules [2, 3]. Sixty-two overlapping peptides of sixteen amino acids (aa) were tested in a coculture of Tregs with syngeneic pDCs (ratio 4:1). Moreover, the repertoire of the TCR of the CD8+ Tregs was studied by flow cytometry analysis and sequencing the CDR3 region.
After six days of culture, two peptides in particular led to the activation of Tregs, as shown by the upregulation of the CD25 molecule (from 25.89% to 29.27% of CD25 expression). These activator peptides were characterized by prominent amino acids (aa) at rather central position, which could result in a large TCR repertoire diversity of the specific Tregs. We showed previously that CD8+CD45RClow Tregs expressed a specific altered V 11 repertoire, with the same CDR3 length in all animals (9 aa). This upregulation was confirmed at the protein level, since 19.9±3.7% of Tregs from a CD40Ig-treated animal expressed the V 11 chain compared to 6.1±2.3% in naïve ones. Sequencing of 160 clones of V 11 TCRs from six long-surviving animals suggested a preferential use of a 9 aa long CDR3 and a particular J region (J 1.6). Interestingly, conserved sequences were frequently found but no common clonotype was shared between animals, suggesting the private nature of the repertoire.
This study demonstrated that CD8+CD45RClow Tregs recognize two potential allogeneic epitopes leading to a private TCR repertoire.
- Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Herve C, Li XL, Heslan M, Usal C, Tesson L, Menoret S: CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007, 117: 1096-1106. 10.1172/JCI28801.PubMed CentralView ArticlePubMedGoogle Scholar
- van Denderen B, Peche H, Gagne K, Usal C, Cuturi MC, Soulillou JP: Identification of immunodominant donor MHC peptides following rejection and donor strain transfusion-induced tolerance of heart allografts in adult rats. Eur J Immunol. 2001, 31: 1333-1339. 10.1002/1521-4141(200105)31:5<1333::AID-IMMU1333>3.0.CO;2-1.View ArticlePubMedGoogle Scholar
- Ballet C, Renaudin K, Degauque N, Mai HL, Boeffard F, Lair D, Berthelot L, Feng C, Smit H, Usal C: Indirect CD4+ TH1 response, antidonor antibodies and diffuse C4d graft deposits in long-term recipients conditioned by donor antigens priming. Am J Transplant. 2009, 9: 697-708. 10.1111/j.1600-6143.2009.02556.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.